Gastrointestinal (GI)

We aim to maintain our strong position in gastrointestinal (GI) treatments by continuing to focus on PPIs. New Nexium line extensions include prevention of re-bleeding in patients with peptic ulcer bleeding, and prevention of low dose aspirin associated peptic ulcer. Our research and development is focused on finding new, innovative ways for treating acid reflux related disease.

Medical need

In the Western World (i.e. Europe and North America combined), according to different estimates, between 10% and 20% of adults suffer from gastresophageal reflux disease (GERD).

The prevalence rate of GERD in Asia is lower but increasing.

Around 40% of patients still suffer from GERD symptoms despite PPI treatment.